Oct. 9 Financial Quick Takes: BioNTech, DBV, MiroBio, Hrain, Beijing Gene+, Ginkgo

BioNTech cuts IPO terms
BioNTech AG now plans to sell fewer shares at a lower price range in a move that could shave nearly $1 billion off the biotech’s postmoney valuation. The company’s latest SEC filing for the offering shows it planning

Read the full 429 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE